Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Retrieved on:
Thursday, November 9, 2023
We also continued to strengthen our board of directors and senior leadership team with multiple key additions during the period.
Key Points:
- We also continued to strengthen our board of directors and senior leadership team with multiple key additions during the period.
- Jasper expects to enroll the first patient by the end of 2023 and to report interim data on multiple cohorts by mid-2024.
- Jasper continued to strengthen the organization with the appointment of Thomas Wiggans as Chairperson of the Board of Directors and Herb Cross as Chief Financial Officer.
- Jasper reported a net loss of $17.5 million, or basic and diluted net loss per share attributable to common stockholders of $0.16, for the three months ended September 30, 2023.